Satya Das, MD, MSCI, discusses the results of a clinical score analysis in patients with neuroendocrine tumors.
Satya Das, MD, MSCI, assistant professor of medicine, Department of Medicine, Division of Hematology/Oncology, Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, discusses the results of a clinical score analysis in patients with neuroendocrine tumors (NETs).
During the 2021 ASCO Gastrointestinal Cancers Symposium, the results of a study evaluating the utility of a clinical score for patients with progressive, well-differentiated NETs who were under consideration for peptide receptor radionuclide therapy (PRRT) with Lutathera (lutetium Lu 177 dotatate) were presented in a virtual presentation.
The results showed that the estimated hazard ratio (HR) for progression-free survival (PFS) was 3.26 for each 2-point increase in clinical score among the 115 patients who received 3 to 4 doses of PRRT, which was considered the full dose. In the 31 patients not treated with PRRT, for each 2-point increase in clinical score, the HR for PFS was 1.37. This suggests that clinical score is predictive for PFS benefit in patients who receive PRRT, but not in those who receive another treatment, Das concludes.